Payer / HTA meeting · Dr. Emiko Quinn

03 Feb 2026 · In person · Dr. Emiko Quinn, A.C. Camargo Cancer Center · MSL Luis Ortega · Lumeva

ReviewedManualENG-0192—

Capture insight from this engagement

Location: A.C. Camargo Cancer Center
Therapeutic area: Neurology
Country: Brazil
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Drug interactions
Switching between CGRP agents
Real-world persistence

Scientific content used

CGRP class review

Questions raised

Any data in patients with medication-overuse headache?
What is the persistence rate at 18 months in real-world cohorts?

Notes

Payer / HTA meeting with general neurologist at A.C. Camargo Cancer Center. Discussed drug interactions, switching between cgrp agents, real-world persistence.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 2
Depth of exchange: 3
Actionability: 2

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0192

Audit history (0)

All create, update and approval events for this record

No audit events in sample data